OncoGynecologyNews.net

OncoGynecology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
Reumabase.it

Results of the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free ...


Recurrent metastatic cervical cancer ( RMCC ), largely due to infections with high-risk types of human papillomavirus ( HPV ), remains an area of high unmet need for patients progressing after greater ...


PIK3CA mutations are common in breast cancer. The aim of a study was to evaluate the correlation of PIK3CA mutational status with pCR in patients with HER2-positive early breast cancer treated with ne ...


Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy ( Trastuzumab [ Herceptin ] and Lapatinib [ Tykerb ] ) ...


Metastatic leiomyosarcomas of uterine or soft-tissue origin have poor prognosis and moderate chemosensitivity. Trabectedin has shown activity in pretreated leiomyosarcoma. Researchers did a single-g ...


Mammography screening may be effective in reducing breast cancer mortality in certain populations, but it can pose harm to women who participate. The limitations are best described as false-positives ...


The CHER-LOB randomized phase II study showed that the combination of Lapatinib ( Tyverb ) and Trastuzumab ( Herceptin ) plus chemotherapy increases the pathologic complete remission ( pCR ) rate comp ...


Alopecia is a common side-effect of chemotherapy and affects quality of life of cancer patients. Some patients and physicians believe that alopecia could be a surrogate marker for response to chemot ...


For a woman in the United States, the average lifetime risk of breast cancer is about 12.3%; the 10-year risks of invasive breast cancer at ages 40, 50, and 60 years are 1.5%, 2.3%, and 3.5% respectiv ...


The International Breast Cancer Study Group ( IBCSG ) has presented results of the randomized phase III SOFT trial at the 2014 San Antonio Breast Cancer Symposium. Suppression of Ovarian Function Tri ...


Due to the lack of prospective randomized data for the management of liver metastases from breast cancer, and the existence of several locoregional techniques, local therapy of liver metastases should ...


As predicted by their DNA-damaging mechanism of action, Platinum compounds are expected to be particularly active in tumours deficient of mechanisms responsible for DNA damage repair, e.g. those witho ...


LABC ( Locally advanced breast cancer ) occurs at first presentation in about one-fifth of breast cancer patients worldwide, with lower incidence in countries with established screening programmes but ...


A new breast cancer vaccine candidate, ( GP2 ), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it ...


Aromatase inhibitors effectively prevent breast cancer recurrence and development of new contralateral tumours in postmenopausal women. Researchers have assessed the efficacy and safety of the aroma ...